The Importance of Pregnancy Planning

Patients with epilepsy can have safe, healthy pregnancies and healthy babies. However, pregnancy planning is essential for minimizing the risk of congenital malformations and adverse neurocognitive outcomes for the fetus while maintaining seizure control for the patient. It is critical that your patients understand the importance of contraception in allowing adequate time for pregnancy planning (which can take up to 12 months).

Topics covered on this page include:


Sexual Health in Epilepsy

Information and counseling from health care providers is valued by patients as they make decisions about their reproductive health plans. Patients report making decisions on pregnancy, breastfeeding, and contraceptive plans based on the recommendations from their health care team and appreciate hearing about the most recent research to support their choices.

There are only a few patients who have reported seizure activity with sexual arousal. For the vast majority of patients, you can reassure them that sexual activity and arousal are safe. Screen every patient of reproductive age, at least once a year, regarding their need for contraception. If patients do not want to become pregnant, refer them to an OB-GYN or a PCP, with an offer to collaborate on care if needed regarding their contraception choices. For patients planning pregnancy in the future, if feasible, refer them to an OB-GYN or an MFM who cares for epilepsy patients in pregnancy for a pre-conception consult.


Contraception Options and Epilepsy Overview

Some contraceptive options may interfere with the efficacy of a patient’s anti-seizure medication (ASM) and impact their seizure control by lowering AMS levels, while some ASMs may impact the efficacy of a patient’s contraception. For patients taking hormonal contraceptives, the use of enzyme-inducing ASMs is associated with an elevated risk of unplanned pregnancies. Some studies found that up to 65% of women with epilepsy reported at least one unplanned pregnancy. Studies describe that overall use of hormonal contraception does not improve or worsen seizure control in patients with epilepsy.

Multiple contraceptive methods with variable effectiveness are available, but some ASMs may impact their effectiveness (see Table 1 below). Hormonal contraception may also reduce available levels of some ASMs. 

Table 1: Effectiveness of Various Contraceptive Methods and Potential Interactions with Enzyme-inducing ASMs

Effectiveness in the general populationMethodPotential
Contraception
(EI-ASM) Interaction
Less than 1 pregnancy per 100 persons in a yearVasectomyNO
Tubal LigationNO
Etonogestrel ImplantYES
Copper IUDsNO
Progestin IUDsNO
6 to 12 pregnancies per 100 persons in a yearDepo-Provera® InjectionYES
PillYES
PatchYES
Vaginal RingYES
DiaphragmNO
10 to 12 pregnancies per 100 persons in a yearMale Condom*NO
Female Condom*NO
Fertility Awareness MethodsNO
SpermicideNO
WithdrawalNO

*Condom use is not affected by enzyme-inducing ASMs. However, condoms are only 85% effective for pregnancy prevention with typical use. They are the only way to prevent sexually transmitted infection (STI) transmission and are recommended for all sexually active patients at risk for STIs.

Table 2: Anti-Seizure Medications (ASMs) That Could Impact Contraception Efficacy

Strong enzyme-inducing ASMs
(These enzyme-inducing ASMs may decrease the efficacy of most hormonal contraception.)
Carbamazepine, Cenobamate, Perampanel, Phenobarbital, Phenytoin, Primidone
Weak enzyme-inducing ASMs
(The effects of the strong enzyme-inducing ASMs are more clear than the effects of weak enzyme-inducing ASMs.)
Clobazam, Eslicarbazepine, Felbamate, Oxcarbazepine, Rufinamide, Topiramate
Non-enzyme-inducing ASMs
(These ASMs do not affect the efficacy of hormonal contraception.)
Brivaracetam, Clonazepam, Ethosuximide, Gabapentin, Lacosamide, Lamotrigine*, Levetiracetam, Pregabalin, Valproic Acid, Zonisamide

*Lamotrigine can have complex interactions; one paper suggested a decrease of progestin levels when used in a combined pill; however, more studies are needed


Preferred Contraception/Hormonal Therapy Options

The following hormonal contraceptives are preferred for patients with epilepsy, especially if they are on enzyme-inducing ASMs.

IUD 

Hormone-eluting intrauterine devices (IUDs) (Mirena®, Kyleena®, Skyla®, and Liletta®) and copper IUDs (Paragard®, Miudella®) are highly effective, long-acting, reversible contraceptive options that will not be affected by ASMs. Both can be used in all patients, whether or not they have been pregnant before. The hormone-eluting IUDs are often preferred by young patients with heavy menstrual bleeding or those who would prefer lighter or no periods. 

The hormone-eluting IUDs have a small amount of progesterone that predominantly works locally, unlike other hormonal contraceptives. The hormone-eluting IUDs will not affect seizure control and will not be significantly affected by enzyme-inducing ASMs.

Depot-Medroxyprogesterone Acetate (Depo-Provera®, “Depo”)

Depot-Medroxyprogesterone is a highly effective contraception and is not substantially affected by any ASM. It is an injection usually administered every 12 weeks. Patients on enzyme-inducing ASMs can be dosed every 10 weeks, which some providers recommend. The injection is available as a parenteral dose administered in clinic, or the patient can be prescribed the subcutaneous option “Depo SC Provera 104®” with teaching on self-administration.

Suppression of ovulation with depot-medroxyprogesterone acetate may have benefits for catamenial epilepsy. Check seizure frequency and consider a shorter dosage interval (e.g., 10 weeks) if seizure frequency increases prior to the next dose (especially if on an enzyme-inducing ASM). Depot-medroxyprogesterone is best for menstrual suppression and can be used in patients with developmental delay.

Etonogestrel Implant (Nexplanon®)

Overall, etonogestrel implants are a highly efficacious form of contraception, with unintended pregnancies of less than 1 per 100 women in a year. However, the efficacy may be lowered by enzyme inducers. The progestin implant has higher efficacy than most other hormonal contraceptives, however case reports indicate that efficacy can be decreased by enzyme-inducing ASMs.


Other Hormonal Contraceptive Options

The following hormonal contraceptives might be LESS effective at preventing pregnancy when paired with enzyme-inducing ASMs and should not be relied on for contraception alone. 

If enzyme-inducing ASMs* are co-prescribed with hormonal contraception options, an additional backup barrier method is recommended. (For lamotrigine, see the section below for special considerations.)

  • Combined (estrogen + progestin) oral contraceptives pill (“the Pill”)
  • Vaginal rings
  • Estrogen + progestin
  • Progestin-only pills (“mini-pill,” “POP”)
    • Norethindrone “Micronor” works via cervical mucus thickening, not anovulation. It is often prescribed in the postpartum period. This medication has a short half-life and is very sensitive to taking the medication at the correct time. Enzyme-inducing ASMs will shorten the half-life and lower the efficacy further. 
    • A newer progestin-only pill is drospirenone (marketed as “Slynd”). This progestin-only pill is newer in the U.S. and some insurance companies do not cover it. With the use of enzyme-inducing ASMs, back-up contraception is recommended.
    • Opill® is the over-the-counter brand of a POP, available to anyone without a prescription. The package warning lists use of anti-seizure medications as a reason

Postpartum Contraceptive Consideration

Patients should avoid estrogen for the first six weeks in the postpartum period to prevent deep vein thrombosis (it is commonly thought that this is due to interfering with breastfeeding, but this is not the case).  


Special Considerations For Lamotrigine

Lamotrigine has complex interactions with hormonal contraception:

Contraceptives with Estrogen Impact on ASM Effectiveness

Estrogen-containing contraceptives (usually in the form of synthetic–ethinyl estradiol) will lower lamotrigine blood levels/concentration and can compromise seizure control if not anticipated. This includes all combined oral contraceptive pills, the vaginal ring, and the estrogen contraceptive patch.

Progestins

Lamotrigine can have complex interactions; one paper suggested a decrease of progestin levels when used in a combined pill, however more studies are needed.

Lamotrigine Clinical Approach

The following is a recommended approach when patients on a stable dose of lamotrigine want to start a hormonal contraceptive that includes estrogen:

Step 1: Check Baseline

Check baseline lamotrigine level (at a convenient time that the patient can use for future consistent blood draws).

  • If lamotrigine dose is <600 mg daily, then increase it by 50% the day they start estrogen-containing contraception. 
  • If lamotrigine dose is >600 mg/day, then divide the increase over a week, and counsel regarding signs of toxicity.

Step 2: One- to Two-week Level Check

After taking estrogen-containing contraception for one to two weeks, check the level again (at a time consistent with the prior level). If the level is 65% or less of baseline, a further increase is warranted.

Example:

  • If lamotrigine dose is 100 mg AM-100 mg PM with a baseline level 4, then start pills and go up to 150 mg AM-150 mg PM. 
  • If in two weeks the level is 2, increase the dose again.

During adjustment and until confirmation that the patient is at their prior baseline blood level, increased seizure precautions (e.g., driving precautions) should be considered. 

When using estrogen-containing contraception with lamotrigine, one approach is to not prescribe a placebo week (extended cycling to increase efficacy, reduce bleeding, and avoid fluctuations in lamotrigine levels (which can go up during the placebo week, particularly if > 3 days).

NOTE: During adjustments, and in patients taking pills with placebo weeks, patients may experience lamotrigine side-effects such as double vision and dizziness, particularly within 1-2 hours of dose. Notifying patients of this in advance can be helpful to avoid concern and guide adjustments. 


Emergency Contraception and Enzyme-Inducing ASMs 

The efficacy of the “Morning after pill” (e.g., Plan B One Step®, Ella®) may be affected by strong enzyme-inducing ASMs. While there is no clear data on this, experts state, “consider doubling the usual single dose of levonorgestrel 1.5 mg.”

Another highly effective form of emergency contraception is urgent placement of an IUD by a gynecologist or family planning clinic. Both hormonal and non-hormonal IUD types can be used as an emergency contraception event without any modification for the concurrent use of enzyme-inducing ASMs. Patients should consult with their OB-GYNs.


Guide Your Patients

People with epilepsy have had to take in a lot of medical information since their diagnosis, and have often been given conflicting information. It is helpful to keep your message clear and positive while emphasizing the importance of contraception for this patient population. Research surrounding ASMs and contraceptives will empower your patients to take charge of their reproductive health and their future. 

Work with the other providers in your patients’ care teams. Input from primary care physicians, neurologists, OB-GYNs, and other specialists is valuable when building a plan. Together you can help your patients take control of their family planning and pregnancy outcomes.

Reviewed by: EPMC Expert Panel, March 2025